By IDSE News Staff
The FDA approved atoltivimab, maftivimab and odesivimab-ebgn (REGN-EB3; Inmazeb, Regeneron), a mixture of three monoclonal antibodies, as the first approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.
Z. ebolavirus is one of four Ebolavirus species that can cause a potentially fatal human disease. Ebola virus is transmitted through direct contact with blood, body fluids and tissues of infected people or wild animals, as well as with